NCIt definition : An orally bioavailable selective inhibitor of mutant forms of and fusion products
involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic
activity. Upon administration, pralsetinib binds to and targets various RET mutants
and RET-containing fusion product. RET gene mutations and translocations result in
the upregulation and/or activation of RET tyrosine kinase activity in various cancer
cell types; dysregulation of RET activity plays a key role in the development and
regression of these cancers.;
UNII : 1WPE73O1WV;
InChIKey : GBLBJPZSROAGMF-BATDWUPUSA-N;
CAS number : 2097132-94-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2097132-94-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;